Dupilumab as promising treatment for prurigo nodularis: current evidences

References

• Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management. Dermatol Clin. 2018;36(3):189–197.
   PubMed Web of Science ®Google Scholar
• Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567–1575.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME2) [Internet]. Bethesda (MD): US National Library of Medicine [2021 Jan]. Available from: https://clinicaltrials.gov/ct2/show/NCT04202679.
   Google Scholar
• ClinicalTrials.gov. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME) [Internet]. Bethesda (MD): US National Library of Medicine [2021 Jan]. Available from: https://clinicaltrials.gov/ct2/show/NCT04183335.
   Google Scholar
• Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28(3):139–150.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Hong H, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3):S28–S36.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990–996.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417.
   PubMed Web of Science ®Google Scholar
• Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol. 2011;165(1):85–91.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Pogatzki-Zahn E, Snels C, et al. There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. Exp Dermatol. 2017;26(10):969–971.
   PubMed Web of Science ®Google Scholar
• Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab - a case series. Med. 2019;6(3):72.
   Google Scholar
• Fachler T, Maria Faitataziadou S, Molho-Pessach V. Dupilumab for pediatric prurigo nodularis: a case report. Pediatr Dermatol. 2020. [published online ahead of print].
   PubMed Web of Science ®Google Scholar
• Kovács B, Rose E, Kuznik N, et al. Dupilumab for treatment-refractory prurigo nodularis. J Dtsch Dermatol Ges. 2020;18(6):618–624.
   Web of Science ®Google Scholar
• Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019;5(5):471–473.
   PubMedGoogle Scholar
• Romano C. Safety and effectiveness of dupilumab in prurigo nodularis. J Investig Allergol Clin Immunol. 2020;31(2):1–7.
   Web of Science ®Google Scholar
• Tanis R, Ferenczi K, Payette M. Dupilumab treatment for prurigo nodularis and pruritis. J Drugs Dermatology. 2019;18(9):940–942.
   PubMed Web of Science ®Google Scholar
• Giura MT, Viola R, Fierro MT, et al. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2020;33(1):e13201.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Lepelletier C, et al. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur Acad Dermatology Venereol. 2019;33(8):e303–e304.
   PubMed Web of Science ®Google Scholar
• Criado PR, Pincelli TP, Criado RFJ. Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. Int J Dermatol. 2020;59(10):e358–e361.
   PubMed Web of Science ®Google Scholar
• Beck KM, Yang E, Sekhon S, et al. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019;155(1):118–120.
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, et al. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020;33(2):e13222.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Qiu CC, Aldrich JL, et al. Use of dupilumab in patients who are HIV-positive: report of four cases. Br J Dermatol. 2019;181(6):1311–1312.
   PubMed Web of Science ®Google Scholar
• Wieser JK, Mercurio MG, Somers K. Resolution of treatment-refractory prurigo nodularis with dupilumab: a case series. Cureus. 2020;12(6):10–15.
   Web of Science ®Google Scholar
• Almustafa ZZ, Weller K, Autenrieth J, et al. Dupilumab in treatment of chronic prurigo: a case series and literature review. Acta Derm Venereol. 2019;99(10):905–906.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Elgash M, Weaver L, et al. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 2019;155(1):121–122.
   PubMed Web of Science ®Google Scholar
• Tilotta G, Pistone G, Caruso P, et al. Our experience with prurigo nodularis treated with dupilumab. J Eur Acad Dermatology Venereol. 2020. [published online ahead of print].
   Web of Science ®Google Scholar
• Tavecchio S, Angileri L, Pozzo Giuffrida F, et al. Efficacy of dupilumab on different phenotypes of atopic dermatitis: one-year experience of 221 patients. J Clin Med. 2020;9(9):2684.
   Web of Science ®Google Scholar
• Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39–45.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatology Venereol. 2020;34(2):e74–e76.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Tavecchio S, Berti E, et al. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2019. [published online ahead of print].
   Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020;31(1):81–84.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed HM, Dupilumab IS. Prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat. 2020. [published online ahead of print].
   PubMed Web of Science ®Google Scholar